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We describe for the first time a case of macrophage activation syndrome (MAS) in a patient with a history of
inflammatory myofibroblastic tumour (inflammatory pseudotumour, IPT) of the lung and thoracic spine. The patient
was admitted to the intensive care unit with a history of prolonged remitting fever, hepatosplenomegaly, bilaterally
enlarged thoracic lymph nodes and an acute severe inflammatory response syndrome (SIRS). Up-regulated cytokine
production (e.g. IL-1ß and IL-6), increased levels of ferritin and circulating soluble interleukin-2 receptor (sIL-2R,
sCD25) led to the differential diagnosis of MAS. Bone marrow aspiration, the main tool for a definite diagnosis,
revealed macrophages phagocytosing haematopoietic cells. Immunosuppressive therapy with corticosteroids and
cyclosporine was an effective treatment in this patient.
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Macrophage activation syndrome (MAS) is a rare but po-
tentially fatal disorder, characterized by combinations of
pancytopoenia, liver failure, coagulopathy and organ dys-
function. It is thought to be caused by the activation and
uncontrolled proliferation of CD8+ lymphocytes and well-
differentiated macrophages, leading to haemophagocytosis
and a so-called cytokine storm [1-3]. The term MAS
describes a condition occurring in a broad spectrum of
diseases, which belong to the histiocytic disorders, e.g.
haemophagocytic lymphohistiocytosis (HLH). Familial or
primary haemophagocytic lymphohistiocytosis has a
known and well-characterized genetic basis, namely a mu-
tation in the perforin gene [4]. It results in the inability of
cytotoxic T lymphocytes (CTLs) or natural killer (NK)
cells to lyse target cells. Secondary HLH can be found in
patients with infections, malignancies and inflammatory
diseases such as juvenile idiopathic arthritis (JIA) or it
may be an adverse effect of certain drugs [5].* Correspondence: ckuppe@ukaachen.de
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reproduction in any medium, provided the orInflammatory myofibroblastic tumours are rare
tumours with different invasive tendencies and growth
capacity [6]. In fact, this tumour entity represents the
non-neoplastic unregulated growth of inflammatory cells
and fibroblasts or myofibroblasts, irrespective of their
organs of origin [7].
Pulmonary inflammatory myofibroblastic tumours
usually consist of a mixed inflammatory infiltrate with
a predominance of plasma cells [8]. Two theories exist
concerning the origin of IPTs. According to one the-
ory, the tumour is in fact a regular inflammatory
process, which follows interstitial pneumonia. Subse-
quently, it transforms into an organized pneumonia
and, eventually, into an inflammatory myofibroblastic
tumour. In support of this hypothesis, production of
IL-6 mRNA and protein by tumour cells in IPT has
been reported in some cases [8,9]. Yet, according to
another hypothesis, some plasma cell granulomas rep-
resent slow-growing mesenchymal tumours with sec-
ondary inflammatory changes.
In this report, we describe for the first time the oc-
currence of MAS in a patient with a history of an in-
flammatory myofibroblastic tumour of the lung and
thoracic spine.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The patient, a 27 year-old male, presented initially to his
general practitioner because of increasing back pain. As
an electrical mechanic he traveled extensively from Ger-
many to China, Russia and South Korea and was mainly
involved in the installation of electronic devices in newly
built tunnels. Due to back pain and an evolving neuro-
logical deficit of the lower extremities, the patient was
admitted to an external orthopaedic department. A mag-
netic resonance imaging (MRI) of the spine revealed an
atypical tumour in the left upper lung lobe encasing the
vertebrae Th3-Th4. A computerized tomography (CT) of
the thorax revealed a mass of 3.9 cm x 2.9 cm in the left
upper lung lobe (Figure 1A, B, arrows). Histological
examination of a biopsy of the mass showed an IPT with
large amounts of histiocytes, lymphocytes and plasma
cells (Figure 1C, D). After neurosurgical therapy, the
neurological deficit in the lower extremities improved
and the patient was discharged. In a second operation,
the lung tumour was removed. Histological examination
of this material also revealed an IPT. Given the extensive
travel history of the patient, various infectious agents
were excluded (mycobacteria, legionella, Borrelia burg-
dorferi, pneumocystis, Epstein-Barr virus (EBV), herpes
simplex virus, human immunodeficiency virus-1/2,
parvovirus, respiratory viruses, cytomegalovirus (CMV)
and other bacteria, stool pathogens and urinary histo-
plasma antigen). During the following two years, the pa-
tient was intermittently treated with corticosteroids, and
low-dose radiation therapy was performed in order toFigure 1 Aspects of the pseudoinflammatory tumour of the lung in t
the upper left lung lobe. (B) A computed tomography of the lung revealed
(C-D) Histological analysis revealed the diagnosis of a pseudoinflammatorycontrol tumour growth locally, as recommended previ-
ously [10].
After two-and-a-half years, the internal fixator was
removed without complications. A few days later, the pa-
tient presented to a general practitioner because of dizzi-
ness and mild fever. The operation wound appeared
normal and laboratory tests revealed no evidence of infec-
tion. During the following two weeks, the symptoms
increased and the patient was admitted to the hospital.
Postoperative spondylodiscitis was ruled out by CT and
MRI of the spine. The CT scan revealed enlarged medias-
tinal lymph nodes and hepatomegaly. Subsequently, he
developed SIRS and was admitted to the intensive care
unit. Blood cultures, initial bone marrow aspiration as well
as a biopsy and transesophageal echocardiography all
came back negative or normal. Histologic examination of
material obtained during mediastinoscopy as well as a
bronchial lavage showed no malignant cells; the CD4/CD8
ratio was not elevated. No granulomas were observed and
sarcoidosis thus appeared unlikely. Subsequently, both
elbows started to appear swollen and hot. A biopsy ruled
out fasciitis but immunohistopathological evaluation
showed histiocytic inflammation with CD68-positive
foamy histiocytes and absence of CD1a immunoreactivity
(excluding a Langerhans cell histiocytosis) (Figure 2 A-C).
A liver biopsy was performed; the tissue showed no signs
of sarcoidosis and only a mild non-specific inflammatory
response. Additionally, there was no evidence for a malig-
nant B- or T-cell lymphoma in subclonal tests using semi-
nested PCRs of the biopsy material from the lungs. Ahe patient. (A) A chest radiography revealed a mass in projection of
a mass in the left lobe of the lung in contact with the thoracic spine.
tumour, with the characteristic spindle-like cell structure of fibroblasts.
Figure 2 Routine and immunohistochemical stainings of biopsies from cubital veins and bone marrow. (A-B) Biopsies of cubital veins
showed complete loss of normal vein architecture with massive infiltration of lymphocytes (arrows in A), histiocytes (arrows in B), macrophages
and fibroblasts. (C-D) Further immunohistochemical analysis revealed massively increased numbers of proliferating Ki-67+/CD68+ macrophages
(arrows in C and D). (E-G) Bone marrow biopsies of the patient revealed haemophagocytosis, the defining criterion of MAS. Characteristically, the
histiocytes showed degenerated and nucleated proerythoblasts within their cytoplasm (arrows E-G).
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hypermetabolic region. Finally, histological evaluation of a
second bone marrow biopsy showed haemophagocytic
histiocytes (Figure 2, E-G).
Flow cytometric analysis revealed the absence of NKT
cells and an increased expression of CD163 on all bone
marrow cells. CD163, a receptor for haemoglobin-
haptoglobin complexes, is involved in clearance and
endocytosis of haemoglobin/haptoglobin complexes by
macrophages and may thereby protect tissues from free
haemoglobin-mediated oxidative damage. The plasma
levels of soluble CD163 in HLH are considerably higherthan those found in infections or autoimmune diseases
[11]. In the peripheral blood, we also found a slight in-
crease of the relative amount of B-lymphocytes as well
as an increased expression of CD63 (degranulation mar-
ker) and CD11b (migration marker on neutrophils) on
bone marrow cells (Figure 3, A-I).
One week after admission, an immunosuppressive
regimen was started including 1 mg/kg body weight
methylprednisolone and 5 mg/kg body weight ciclos-
porin. The fever decreased over several days after initi-
ation of therapy and laboratory values normalized
(Table 1). After two weeks of therapy, the cytokine levels
Figure 3 Flow cytometric analysis of bone-marrow cells and morphology of antigen-presenting cells (APC) from long-term-cultures. (A)
NKT (CD3+/CD56+ cells) were no longer present in the bone marrow of the patient. (B-C) Images show Giemsa-stained cytospin preparations of
28-day-cultured haemophagocytes with characteristic autophagy vacuoles and inclusion bodies containing undigested phagocytozed material
(arrows). (D-I) Further FACS analysis revealed a high expression of CD63 on all BMCs and also an increased expression of CD11b on granulocytes.
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reduced (Table 2). The patient was maintained on 5 mg
prednisolone and cyclosporine 2-6 mg/kg/d and to date
he has had no further relapses for over a year.Table 1 Laboratory Values
Variable fever episode after
Haematocrit (%) 0,25 0,34
White-cell count (10^6/l) 15,10 13,10
Platelet count (10^6/l) 587 519
Ferritin (μg/l) 1043 230
Triglycerides (mg/dl) 68 127
IL2R (kU/l) > 7200 2000
IL6 (ng/l) 1500 250
CRP (mg/l) >230 + 53
PCHE (U/l) 918 3218
Prothombin time (INR)
Fibrinogen (g/l) 4,8 n.d.Discussion
In acquired cases of macrophage activation syndrome
(MAS), the clinical course is usually rapidly progressive
with multi-system organ failure often occurring within2 weeks after 5 months normal range
0,43 0.4–0.54
11,9 4.3–10.0
235 150–350
204 30–400
208 < 200
690 223–710
n.d. < 7
10 < 5
9495 5320–12920
0.8–1.1
n.d. 2.0–4.5
Table 2 Diagnostic criteria for HLH*
(1) Fever Manifestations in the patient described quotidian fever over several weeks
(2) Splenomegaly hepatosplenomegaly
(3) Cytopenia involving two or more cell lines haemoglobin < 9.0 d/dL, no other
(4) Hypertriglyceridaemia or hypofibrinogenaemia no
(5) Haemophagocytosis yes
(6) Hepatitis yes
(7) Low or absent natural killer cell activity yes
(8) Serum ferritin level > 500 μg 1043 μg/L
(9) Soluble CD25 (sIL-2 receptor) > 2500 U/ml > 7200 U/ml
*according to HLH-2004 criteria (Henter JI et al.).
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syndrome is caused by dysregulated macrophage-
lymphocyte interaction, which leads to uncontrolled
proliferation of macrophages and CD8+ T-cells with
up-regulated release of monokines, mainly of the
interleukin-1 family (interleukin-1α and 1β and inter-
leukin-18), whereas levels of T-cell–derived cytokines,
such as interferon-γ, are much less increased [12]. Re-
cently, cell-type specific characteristics of ‘immature
antigen presenting cells (APC)’ from patients with MAS
have been described. It is known that tumours (espe-
cially fibroblasts) can express M-CSF, which could influ-
ence the development of immature phagocytic APCs
[13]. In our patient, fulminant MAS was present for ap-
proximately 3 weeks until the initiation of therapy. The
standard definition of HLH requires the presence of at
least five of nine clinical criteria. Our patient fulfilled
seven of these criteria (Table 2). Additionally, we could
find an extramedullary manifestation of MAS, namely a
proliferative (Ki-67-positive) histiocytic cell infiltrate in
both elbows of the patient. Typically in the acute phase
of the cytokine storm, lymphohistiocytic infiltrates can
be found in the spleen, lymph nodes and bone marrow
[5]. A CD1a staining of the cubital veins remained nega-
tive, thus making the diagnosis of Langerhans-cell histio-
cytosis unlikely. In the absence of a clinically apparent
malignancy, in addition to MAS, the differential diagno-
sis for fever with splenomegaly, liver failure and bilat-
erally enlarged lymph nodes includes premalignant,
inflammatory, infectious, genetic and toxic causes. All of
these could be ruled out on the basis of the history and
laboratory studies. Acute EBV and CMV infections are
associated with fever, pharyngitis, lymphadenopathy and
fatigue and would likely have been self-limited. The dif-
ferential diagnosis of sarcoidosis was mainly ruled out
because no granulomas could be found in any of the bi-
opsies. Furthermore, the bone marrow did not show any
premalignant, infiltrative or infectious processes.
Several treatment options have been reported in the
literature for MAS. A treatment protocol from the His-
tiocyte Society recommends a therapeutic regimen ofetoposide, dexamethasone and cyclosporine [14]. In
other cases, high-dose steroids, cyclosporine, antihuman
thymocyte globulin (ATG), intravenous immune globulin
(IVIG), plasma exchange and allogeneic bone marrow
transplantation have been described. Recently, treatment
with an IL-1 beta receptor antagonist (anakinra) was
successful in several cases of severe paediatric rheumatic
disease-associated MAS [15,16]. It can be speculated
that other immunomodulatory therapies (alemtuzumab,
infliximab, daclizumab, selective IL-1 and IL-6 antago-
nists) might influence the course of the disease benefi-
cially, but clinical trials remain almost impossible due to
the rare occurrence of the disease.
In summary, we describe the first patient with macro-
phage activation syndrome (MAS) and a history of an
inflammatory myofibroblastic tumour, which could be
controlled by immunosuppressive therapy including
steroids and cyclosporine.
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